Bank of Montreal’s Outlook Therapeutics OTLK Stock Holding History

Bank of Montreal’s Portfolio OTLK Stock Details OTLK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-100	Closed	-$3K	–	4961
2019 Q3	$3K	Buy	+100	New	+$3.86K	﹤0.01%	4616

Other funds holding OTLK

LVW Advisors Pittsford, New York $1.16B AUM 26.37% 1-Year Est. Return

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

LTFS

Ladenburg Thalmann Financial Services Miami, Florida $15.9B AUM 25.16% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

DFPG Investments Sandy, Utah $1.28B AUM 27.55% 1-Year Est. Return

Bank of Montreal's OTLK Position: Q4 2019 in Review

Bank of Montreal sold out of Outlook Therapeutics (OTLK) in Q4 2019, closing a stake of 100 shares — an estimated $3K sold.

Bank of Montreal first reported a position in OTLK in Q3 2019 and held it in 1 quarter. The position peaked at $3K in Q3 2019. 17 funds tracked by Wall St. Rank hold OTLK as of Q4 2019.

Bank of Montreal reported no remaining Outlook Therapeutics position as of Q4 2019 after selling out during the quarter.
Bank of Montreal sold 100 Outlook Therapeutics shares in Q4 2019, an estimated $3K.
Bank of Montreal first reported a position in Outlook Therapeutics in Q3 2019 and held it in 1 quarter.
Bank of Montreal's Outlook Therapeutics position peaked at $3K in Q3 2019.
17 funds tracked by Wall St. Rank held Outlook Therapeutics as of Q4 2019.

Based on Bank of Montreal's 13F filing for Q4 2019, filed 10 Feb 2020.